罂粟碱硫酸盐 | 2053-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 罂粟碱硫酸盐
• 英文名称: Papaverine sulfate
• 英文别名: 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;sulfuric acid
• CAS: 2053-26-1
• 化学式: C20H23NO8S
• 分子量: 437.5
• InChiKey: KYFCEOITJFJQGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.21
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• NOVEL COMPOUNDS AND METHODS FOR MODULATING UBIQUITINATION
  申请人：Johann Wolfgang Goethe-Universität Frankfurt am Main

  公开号：EP3299460A1

  公开（公告）日：2018-03-28

  The present invention pertains to the modification of the eukaryotic ubiquitin system by using the bacterial virulence factor SdeA and variants and mutants thereof. The invention is based on the phosphodiesterase activity of SdeA, which catalyzes a phospho-ribosylation (or simply "ribosylation") event of ubiquitin and ubiquitin-like proteins. The invention provides SdeA proteins and mutants without said phosphodiesterase activity, as well as medical applications of these recombinant proteins, their encoding nucleic acids, ribosylated ubiquitin proteins, and compounds which may act as selective or non-selective phosphodiesterase inhibitors.

  本发明涉及利用细菌毒力因子 SdeA 及其变体和突变体对真核生物泛素系统进行修饰。 本发明以 SdeA 的磷酸二酯酶活性为基础，SdeA 可催化泛素和泛素样蛋白的磷酸核糖化（或简称 "核糖化"）过程。 本发明提供了没有上述磷酸二酯酶活性的 SdeA 蛋白和突变体，以及这些重组蛋白、其编码核酸、核糖基化泛素蛋白和可作为选择性或非选择性磷酸二酯酶抑制剂的化合物的医学应用。
• Compositions and methods for preventing and treating conditions
  申请人：Ansella Therapeutics, Inc.

  公开号：US10668046B2

  公开（公告）日：2020-06-02

  Provided herein are compositions comprising a stable water-in-silicone emulsion, and methods and kits comprising the compositions for treating conditions.

  本文提供了包含稳定的硅酮水乳剂的组合物，以及包含该组合物的用于治疗疾病的方法和试剂盒。
• Pharmaceutical compositions and methods of treating cardiovascular diseases
  申请人：Cardix Therapeutics LLC

  公开号：US10758544B2

  公开（公告）日：2020-09-01

  Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.

  本文提供了一种药物组合物，该组合物包含两种或两种以上化合物，其中每种化合物都是独立的磷酸二酯酶抑制剂、腺苷受体拮抗剂、钙通道阻滞剂、组胺H1-受体激动剂、组胺H2-受体激动剂、组胺H3-受体拮抗剂或β2-肾上腺素受体激动剂。本文还提供了一种治疗、预防或改善受试者心血管疾病的方法，包括向有需要的受试者施用两种或多种化合物，其中每种化合物都是独立的磷酸二酯酶抑制剂、腺苷受体拮抗剂、钙通道阻滞剂、组胺H1-受体激动剂、组胺H2-受体激动剂、组胺H3-受体拮抗剂或β2-肾上腺素受体激动剂。
• Cardioplegic solution
  申请人：——

  公开号：US20040018245A1

  公开（公告）日：2004-01-29

  Use of potassium for the production of a cardioplegic solution for the prevention of stone heart development during acute cardiac ventricular fibrillation in connection with cardiopulmonary resuscitation is described, as well as a cardioplegic solution comprising potassium and a method for the prevention of stone heart developement during acute cardiac ventricular fibrillation in connection wiht cardiopulmonary resuscitation.

  介绍了使用钾来生产预防急性心室颤动与心肺复苏过程中结石性心脏病发生的心肌溶液，以及一种含有钾的心肌溶液和一种预防急性心室颤动与心肺复苏过程中结石性心脏病发生的方法。
• Use of papaverine-like vasodilator and pharmaceutical composition
  申请人：Gross Dorothea

  公开号：US20060058345A1

  公开（公告）日：2006-03-16

  The invention concerns the use of papaverine-like vasodilator for the production of a pharmaceutical composition for the treatment of ophthalmological dysfunctions which are linked to circulatory disturbances of the eye or which are to be attributed to circulatory disturbances of the eye, wherein the pharmaceutical composition is to be applied topically to the eye. The invention further concerns a pharmaceutical composition which includes papaverine-like vasodilator and pharmacologically compatible viscosity regulator.

  本发明涉及使用类罂粟碱血管扩张剂生产一种药物组合物，用于治疗与眼部循环障碍有关或可归因于眼部循环障碍的眼科功能障碍，其中该药物组合物可局部用于眼部。本发明还涉及一种药物组合物，其中包括类木瓜碱血管扩张剂和药理兼容的粘度调节剂。